莱美药业(300006) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥190,896,082.72, a decrease of 27.81% compared to the same period last year[4]. - The net profit attributable to shareholders was -¥456,929.47, representing a decline of 103.91% year-on-year[4]. - The basic earnings per share for the period was -¥0.0004, down 103.60% from the previous year[4]. - Total operating revenue for Q3 2023 was ¥644,756,058.18, a decrease of 3.3% from ¥670,853,551.45 in the same period last year[27]. - Net loss for Q3 2023 was ¥63,966,209.62, compared to a net loss of ¥44,728,469.91 in Q3 2022, representing an increase in loss of 42.9%[28]. - The total comprehensive income for the third quarter was -63,966,209.62 CNY, compared to -44,728,469.91 CNY in the previous year, indicating a decline of approximately 42.9%[29]. - Basic and diluted earnings per share were both -0.0516 CNY, compared to -0.0354 CNY in the previous year, indicating a worsening performance[29]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,891,884,789.22, a decrease of 5.34% from the end of the previous year[4]. - The company's total assets decreased to ¥2,891,884,789.22 from ¥3,054,984,574.17 year-on-year, a decline of 5.3%[25]. - Total liabilities decreased to ¥787,823,476.56 from ¥870,020,565.44, a reduction of 9.4%[25]. - The total equity attributable to shareholders decreased by 2.46% to ¥2,072,120,829.39 compared to the end of the previous year[4]. - The company's equity attributable to shareholders decreased to ¥2,072,120,829.39 from ¥2,124,446,116.48, a decline of 2.5%[25]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥39,187,498.89, with no comparative data available[4]. - The net cash flow from operating activities was 39,187,498.89 CNY, a significant improvement from -26,539,836.25 CNY in the same period last year[31]. - Cash inflow from operating activities totaled 1,136,154,246.33 CNY, up from 1,071,511,372.34 CNY, reflecting an increase of about 6.0%[30]. - The cash outflow from operating activities was 1,096,966,747.44 CNY, slightly down from 1,098,051,208.59 CNY, showing a marginal decrease of 0.1%[31]. - The net cash flow from investing activities was 6,246,378.35 CNY, recovering from a loss of -22,267,652.60 CNY in the previous year[31]. - The net cash flow from financing activities was -79,519,540.54 CNY, a decline from 177,280,866.53 CNY in the same period last year[31]. - The ending balance of cash and cash equivalents was 761,774,681.24 CNY, an increase from 686,921,451.70 CNY year-over-year[31]. Operational Metrics - Total operating costs for Q3 2023 were ¥684,021,711.19, down 7% from ¥735,121,204.64 year-on-year[27]. - Research and development expenses for Q3 2023 were ¥53,968,857.00, slightly down from ¥54,423,054.23 in the previous year[27]. - The company reported a significant increase in financial expenses, totaling -¥18,180,698.93, primarily due to increased interest income[13]. - Interest income increased significantly to ¥27,035,213.71 from ¥10,493,509.95 year-on-year, marking a growth of 157.7%[28]. - The company reported a significant increase in other income to ¥37,709,326.78 from ¥30,310,850.12, an increase of 24.5%[28]. Shareholder Information - The company has a total of 41,212 common shareholders at the end of the reporting period[15]. - The company recognized a non-operating income of ¥79,543.56, a decrease of 99.62% year-on-year due to a prior year legal settlement[13]. Inventory and Receivables - Accounts receivable decreased to ¥288,426,739.34 from ¥331,453,977.34, reflecting a reduction of about 12.9%[22]. - Inventory decreased to ¥173,841,963.19 from ¥202,401,066.62, indicating a decline of approximately 14.1%[22]. - The company’s prepayments decreased to ¥26,126,929.07 from ¥33,234,912.16, reflecting a decline of approximately 21.3%[22]. - The company reported a total of ¥321,593,320.26 in other receivables as of September 30, 2023, compared to ¥312,518,677.07 at the beginning of the year, showing a slight increase of about 2.5%[22]. - The company’s financing receivables increased to ¥24,663,098.00 from ¥15,254,756.31, indicating a growth of about 61.5%[22]. Legal Matters - The company and its subsidiary are appealing a first-instance judgment in a lawsuit against Changchun Haiyue Pharmaceutical Co., Ltd.[20]. - The company is currently involved in litigation regarding exclusive sales agency rights for tadalafil, with ongoing appeals in higher courts[20]. Product Development - The company received approval for the clinical trial of its mRNA-based therapeutic vaccine product CUD002, which targets tumor neoantigens[21]. - The company’s paclitaxel injection (5ml:30mg) passed the consistency evaluation for generic drug quality and efficacy, receiving approval from the National Medical Products Administration[19].